Globus Medical Inc.
GMED evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GMED—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GMED
Globus Medical Inc. is a musculoskeletal solutions company focused on developing and commercializing products for spinal surgery and orthopedic procedures, with a strong financial position and ongoing investments in sales force expansion and product launches.
Key risk: FDA regulatory risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$11.14B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for Globus Medical Inc..
Globus Medical Inc. is a musculoskeletal solutions company focused on developing and commercializing products for spinal surgery and orthopedic procedures, with a strong financial position and ongoing investments in sales force expansion and product launches.
- Cash & equivalents of $507.7M as of 2026-06-30 [sec].
- Total revenue of $789.6M for the quarter ended 2026-06-30 [sec].
- Net income of $151.6M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $4,295.7M as of 2026-06-30 [sec].
- Total debt of $0.4M as of 2026-06-30 [sec].
What works
- Strong cash position of $507.7M and minimal debt of $0.4M as of 2026-06-30 provide financial flexibility [sec].
- Consistent profitability with net income of $151.6M in the latest quarter [sec].
- Management expects to continue investing in surgical sets, U.S. sales force, and international expansion [sec_mda · as of 2026-08-06].
What to weigh
- The company faces risks related to FDA interactions, as noted in forward-looking statements [sec · filed 2024-08-13].
- Future liquidity needs may require additional debt or equity financing, which could dilute shareholders [sec_mda · as of 2026-08-06].
- Operating expenses, including selling, general and administrative costs, are expected to increase with expansion efforts [sec_mda · as of 2025-02-20].
Risks & what to watch (3)›
Key risks
- FDA regulatory risk — Forward-looking statements highlight risks related to FDA interactions and potential material impact on financial results [sec · filed 2024-08-13].
- Need for additional liquidity — Future liquidity may require debt or equity financing, which could affect capital structure [sec_mda · as of 2026-08-06].
- Expansion cost pressure — Investments in sales force and international markets may increase operating expenses [sec_mda · as of 2025-02-20].
What to watch
- FDA updates and regulatory developments regarding product approvals [sec · filed 2024-08-13].
- Quarterly financial results and cash flow trends, especially operating cash flow [sec_mda · as of 2025-11-06].
- Progress in U.S. sales force expansion and international market penetration [sec_mda · as of 2026-08-06].
- Any new debt or equity financing activities [sec_mda · as of 2026-08-06].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Globus Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Globus Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.15 · 2% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
598
Total value held
$9.34B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 15,246,190 | $1.31B |
| blackrock, inc. | 10,497,414 | $904.5M |
| vanguard capital management llc | 10,065,464 | $867.2M |
| vanguard portfolio management llc | 4,879,459 | $420.4M |
| state street corp | 3,590,372 | $309.3M |
| bank of montreal /can/ | 2,307,181 | $198.8M |
| geode capital management, llc | 2,112,124 | $182.0M |
| citadel advisors llc | 2,029,114 | $174.8M |
| william blair investment management, llc | 2,009,763 | $173.2M |
| alliancebernstein l.p. | 1,750,832 | $152.9M |
Showing top 10 of 598 institutional holders of Globus Medical Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 2.8%
- Days to cover
- 3.0
- Shares short
- 3,120,512
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GMED short interestGovernance
Frequently asked questions
What is the AI investment thesis for Globus Medical Inc.?
Globus Medical Inc. is a musculoskeletal solutions company focused on developing and commercializing products for spinal surgery and orthopedic procedures, with a strong financial position and ongoing investments in sales force expansion and product launches.
Who is the CEO of Globus Medical Inc.?
Mr. Keith W. Pfeil is the chief executive officer of Globus Medical Inc. (GMED).
Where is Globus Medical Inc. headquartered?
Globus Medical Inc. (GMED) is headquartered in Audubon, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.